Posted by Michael Wonder on 09 Sep 2024
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with unresectable advanced, claudin 18.2 positive HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
9 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of zolbetuximab in combination with chemotherapy in the NHS in England.
For the time being, zolbetuximab, when used in combination with fluoropyrimidine- and platinum-based chemotherapy, is not recommended for the first-line treatment of adults with locally advanced, unresectable or metastatic claudin 18.2 positive, HER2 negative, gastric or gastro-oesophageal junction adenocarcinoma.
